These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 11758498

  • 21. Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes.
    Curr Opin Rheumatol; 1995 Nov; 7(6):B108-13. PubMed ID: 8579964
    [No Abstract] [Full Text] [Related]

  • 22. [Relations between Raynaud's disease and scleroderma in the framework of immunological research].
    FARINELLI A, RIPA R, GRANDI L.
    Arcisp S Anna Ferrara; 1960 Nov; 13(Suppl 6)():1491-517. PubMed ID: 13698198
    [No Abstract] [Full Text] [Related]

  • 23. Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes.
    Curr Opin Rheumatol; 1996 Nov; 8(6):B170-6. PubMed ID: 9018466
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Aberrant immune response with consequent vascular and connective tissue remodeling - causal to scleroderma and associated syndromes such as Raynaud phenomenon and other fibrosing syndromes?
    Durmus N, Park SH, Reibman J, Grunig G.
    Curr Opin Rheumatol; 2016 Nov; 28(6):571-6. PubMed ID: 27548652
    [Abstract] [Full Text] [Related]

  • 26. Tako-tsubo-like syndrome in systemic sclerosis: a sign of myocardial Raynaud phenomenon?
    Melchiorre D, Bernardo P, Conforti ML, Comunian C, Nacci F, Guiducci S, Fiori G, Moggi-Pignone A, Gensini GF, Matucci-Cerinic M.
    Ann Rheum Dis; 2008 Jun; 67(6):898-9. PubMed ID: 18474662
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Systemic sclerosis/scleroderma: a treatable multisystem disease.
    Hinchcliff M, Varga J.
    Am Fam Physician; 2008 Oct 15; 78(8):961-8. PubMed ID: 18953973
    [Abstract] [Full Text] [Related]

  • 31. [Sclerodermic acrosyndromes].
    Carpentier PH.
    Rev Prat; 2002 Nov 01; 52(17):1891-5. PubMed ID: 12532865
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Scleroderma. Nosology and classification].
    Fiessinger JN, Housset E.
    Rev Prat; 1975 May 01; 25(25):1925-6, 1929-30, 1933. PubMed ID: 1135582
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Raynaud's phenomenon and scleroderma; a case report and psychodynamic formulation.
    RICHARDSON HB.
    Psychoanal Rev; 1955 Jan 01; 42(1):24-38. PubMed ID: 14371880
    [No Abstract] [Full Text] [Related]

  • 36. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S, Wigley FM.
    Curr Opin Rheumatol; 2007 Nov 01; 19(6):611-8. PubMed ID: 17917543
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Systemic sclerosis and multiple sclerosis.
    Spadaro A, Sensi F, Barrella M, Francia A.
    J Neurol; 1999 Jun 01; 246(6):497-9. PubMed ID: 10431778
    [No Abstract] [Full Text] [Related]

  • 39. Classification and pathogenesis of scleroderma.
    Winkelmann RK.
    Mayo Clin Proc; 1971 Feb 01; 46(2):83-91. PubMed ID: 4925984
    [No Abstract] [Full Text] [Related]

  • 40. [Tumor necrosis factor alpha in systemic scleroderma].
    Alekperov RT, Timchenko AV, Nasonov EL.
    Klin Med (Mosk); 2003 Feb 01; 81(12):4-7. PubMed ID: 14971148
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.